Congreve, M.S. et al. “A ‘Rule of Three’ for fragment-based lead discovery?.” Drug Discovery Today 8, no. 19 2003: 876–877. DOI: 10.1016/S1359-6446(03)02831-9.

/in ,

Congreve, M.S. et al. “A ‘Rule of Three’ for fragment-based lead discovery?.” Drug Discovery Today 8, no. 19 2003: 876–877. DOI: 10.1016/S1359-6446(03)02831-9.

Frederickson M., Vuillard, L. et al. “Novel selenium containing non-detergent sulphobetaines.” Tetrahedron Letters 44, no. 43 2003: 7925–7928. DOI: 10.1016/j.tetlet.2003.09.004.

/in ,

Frederickson M., Vuillard, L. et al. “Novel selenium containing non-detergent sulphobetaines.” Tetrahedron Letters 44, no. 43 2003: 7925–7928. DOI: 10.1016/j.tetlet.2003.09.004.

Hartshorn, MJ. “AstexViewer™: a visualisation aid for structure-based drug design.” Journal of Computer-Aided Molecular Design 16, no. 12 2003: 871-881. DOI: 10.1023/A:1023813504011.

/in ,

Hartshorn, MJ. “AstexViewer™: a visualisation aid for structure-based drug design.” Journal of Computer-Aided Molecular Design 16, no. 12 2003: 871-881. DOI: 10.1023/A:1023813504011.

Sharff A. , Jhoti, H. “High-throughput crystallography to enhance drug discovery.” Current Opinion in Chemical Biology 7, no. 3 2003: 340–345. DOI: 10.1016/S1367-5931(03)00062-0.

/in ,

Sharff A. , Jhoti, H. “High-throughput crystallography to enhance drug discovery.” Current Opinion in Chemical Biology 7, no. 3 2003: 340–345. DOI: 10.1016/S1367-5931(03)00062-0.

van Montfort, R.L.M., et al. “Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B.” Nature 423 2003: 773-777. DOI: 10.1038/nature01681.

/in ,

van Montfort, R.L.M., et al. “Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B.” Nature 423 2003: 773-777. DOI: 10.1038/nature01681.

Verdonk, M. L., et al. “Improved protein–ligand docking using GOLD.” Proteins: Structure, Function, and Bioinformatics 52, no. 4 2003: 609–623. DOI: 10.1002/prot.10465.

/in ,

Verdonk, M. L., et al. “Improved protein–ligand docking using GOLD.” Proteins: Structure, Function, and Bioinformatics 52, no. 4 2003: 609–623. DOI: 10.1002/prot.10465.

Watson P. Verdonk, M. , Hartshorn M.J. “A web-based platform for virtual screening.” Journal of Molecular Graphics and Modelling 22, no. 1 2003: 71–82. DOI: 10.1016/S1093-3263(03)00137-2.

/in ,

Watson P. Verdonk, M. , Hartshorn M.J. “A web-based platform for virtual screening.” Journal of Molecular Graphics and Modelling 22, no. 1 2003: 71–82. DOI: 10.1016/S1093-3263(03)00137-2.

Williams, P.A., et al. “Crystal structure of human cytochrome P450 2C9 with bound warfarin.” Nature 424, no. 6947 2003: 464-468. DOI: 10.1038/nature01862.

/in ,

Williams, P.A., et al. “Crystal structure of human cytochrome P450 2C9 with bound warfarin.” Nature 424, no. 6947 2003: 464-468. DOI: 10.1038/nature01862.

Yon J., Jhoti, H. “High-throughput structural genomics and proteomics: where are we now?.” Targets 2, no. 5 2003: 201–207. DOI: 10.1016/S1477-3627(03)02348-1.

/in ,

Yon J., Jhoti, H. “High-throughput structural genomics and proteomics: where are we now?.” Targets 2, no. 5 2003: 201–207. DOI: 10.1016/S1477-3627(03)02348-1.

Blundell T.L., Jhoti, H. et al. “High-throughput crystallography for lead discovery in drug design.” Nature Reviews Drug Discovery 1 2002: 45-54. DOI: 10.1038/nrd706.

/in ,

Blundell T.L., Jhoti, H. et al. “High-throughput crystallography for lead discovery in drug design.” Nature Reviews Drug Discovery 1 2002: 45-54. DOI: 10.1038/nrd706.